COST OF 5-YEAR PROGRESSION FREE SURVIVAL ANALYSIS OF TRIPLE-CLASS EXPOSED PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL IN THE BRAZILIAN PRIVATE HEALTH SYSTEM
Author(s)
PEDRO C. AGOSTINHO, MBA1, Beatriz Borba, MBA1, Carlos A. Rangel, BSc2, INGRID RODRIGUES, MBA1;
1Johnson & Johnson, São Paulo, Brazil, 2Johnson & Johnson, Panama City, Panama
1Johnson & Johnson, São Paulo, Brazil, 2Johnson & Johnson, Panama City, Panama
OBJECTIVES: Estimate the cost required to maintain patients alive and progression-free over a 60-month time horizon, when treated with ciltacabtagene autoleucel (cilta-cel) versus real-world physician’s choice for refractory/relapsed triple-class exposed (TCE) patients with multiple myeloma (MM). The analysis considered the Brazilian private health system’s perspective.
METHODS: A partitioned survival model was developed on Microsoft Excel for this analysis. Efficacy inputs were derived from the latest CARTITUDE-1 (phase 1b/2, n=97) data and the LocoMMotion trial (prospective study of real-world clinical practice, n=248, 91 unique regimens were used in the first line of treatment after enrollment). The progression free survival (PFS) Kaplan-Meier curves of both trials were extrapolated. Drug acquisition costs followed the local official price list (2025) and drug dosing was aligned with the local regulatory agency approved labels. Only drug acquisition costs were considered. To calculate the cost of the LocoMMotion arm, the cost of the 64% most representative regimens was calculated and weighed according to its overall representativeness. The estimated cost required to maintain patients alive and progression-free over a 60-month time horizon was calculated by dividing the total drug cost by the proportion of patients alive and progression-free at the 60th month for each arms.
RESULTS: At 60 months, 33% of cilta-cel patients remained alive and progression-free, while the extrapolated PFS for the LocoMMotion regimens demonstrated an estimation of 2,55%. Cilta-cel showed lower cost required to maintain patients alive and progression-free versus the LocoMMotion regimens (BRL 8.9 million [M]) vs BRL 21.4 M, respectively).
CONCLUSIONS: Cilta-cel demonstrated lower estimated cost to maintain patients alive and progression-free over a 60-month time horizon, compared with the LocoMMotion regimens. Given its cost profile and reported PFS as evaluated, cilta-cel may represent an optimal treatment for MM patients who are triple-class within the Brazilian private health system.
METHODS: A partitioned survival model was developed on Microsoft Excel for this analysis. Efficacy inputs were derived from the latest CARTITUDE-1 (phase 1b/2, n=97) data and the LocoMMotion trial (prospective study of real-world clinical practice, n=248, 91 unique regimens were used in the first line of treatment after enrollment). The progression free survival (PFS) Kaplan-Meier curves of both trials were extrapolated. Drug acquisition costs followed the local official price list (2025) and drug dosing was aligned with the local regulatory agency approved labels. Only drug acquisition costs were considered. To calculate the cost of the LocoMMotion arm, the cost of the 64% most representative regimens was calculated and weighed according to its overall representativeness. The estimated cost required to maintain patients alive and progression-free over a 60-month time horizon was calculated by dividing the total drug cost by the proportion of patients alive and progression-free at the 60th month for each arms.
RESULTS: At 60 months, 33% of cilta-cel patients remained alive and progression-free, while the extrapolated PFS for the LocoMMotion regimens demonstrated an estimation of 2,55%. Cilta-cel showed lower cost required to maintain patients alive and progression-free versus the LocoMMotion regimens (BRL 8.9 million [M]) vs BRL 21.4 M, respectively).
CONCLUSIONS: Cilta-cel demonstrated lower estimated cost to maintain patients alive and progression-free over a 60-month time horizon, compared with the LocoMMotion regimens. Given its cost profile and reported PFS as evaluated, cilta-cel may represent an optimal treatment for MM patients who are triple-class within the Brazilian private health system.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE522
Topic
Economic Evaluation
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology